Natera says finalized MolDx coverage expands Prospera surveillance testing for kidney, heart, lung transplants

• Natera flagged a final MolDx local coverage determination (L40060) expanding Medicare coverage for Prospera surveillance testing in solid organ transplants.
• Policy takes effect Aug. 30, 2026, raising allowed surveillance testing frequency across kidney, heart, and lung transplant monitoring.
• Kidney coverage set at 6 tests in year 1, then 4 per year in years 2-3; heart at 12 in year 1, then 4 per year.
• Lung coverage set at 12 tests in year 1, then 4 per year in years 2-3 for single or bilateral transplants.
• Final policy exceeds the July 2025 draft, which proposed 2 tests per year in years 2-3 across indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.